ReviewMetabolic brain disease2026
The alteration of brain function in overweight/obese individuals and the neurological benefit of thymoquinone: uncovering molecular mechanisms.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overweight and obesity are complicated metabolic disorders associated with negative impacts on the brain and its function, including cognitive and memory abilities. Herbal medicines are plant-based bioactive compounds produced by plants. Natural food components with antioxidant activity show promise as alternative treatments for a number of illnesses, including brain diseases. Thymoquinone (TQ) is the main bioactive constituent of essential oils produced from Nigella sativa seeds. TQ possesses numerous biological and pharmacological activities, including antioxidant, anti-inflammatory, antihyperglycemic, and immunomodulatory effects, with neuroprotective effects against various neurodegenerative diseases and pathological conditions of the brain. Several studies have investigated the pharmacological activities of TQ; however, its neuroprotective molecular signaling pathways have not been fully described, and several issues remain to be clarified. The current review summarizes the most recent information related to the important molecular signaling pathways by which TQ protects brain function, particularly in overweight/obese individuals. In conclusion, TQ improved the activity of antioxidant enzymes, maintained redox equilibrium and decreased neuroinflammation and apoptosis via various signaling pathways. Numerous proteins, including nuclear factor erythroid 2–related factor 2 (Nrf2), nuclear factor kappa B (NF-κB), toll-like receptor 4 (TLR4), and mitogen-activated protein kinase (MAPK), are crucial for the TQ signaling pathway to prevent brain problems. Although these proteins represent a novel treatment approach, there are still issues with their clinical applicability in various diseases. Researchers should perform further research to determine the additional activity of TQ for the development of clear strategies for the prevention and treatment of brain dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.